Recent research reports from multiple international investment firms have expressed positive views on the clinical data and commercial prospects of CStone Pharmaceuticals' core investigational product, CS2009. Jefferies maintained a "Buy" rating with a target price of HK$20, while Goldman Sachs also reiterated a "Buy" rating, setting a target price of HK$9.44. Both reports highlighted that the PD-1/VEGF/CTLA-4 trispecific antibody CS2009 has demonstrated outstanding efficacy and a favorable safety profile across multiple indications, positioning it as a key driver for future business development deals and potential value reassessment. Clinical data from Phase I/II studies indicate strong competitiveness for CS2009. Jefferies noted that in first-line non-small cell lung cancer patients with PD-L1 TPS ≥50%, the objective response rate reached 90% with monotherapy, accompanied by a disease control rate of 100%. The firm also observed that the 25% ORR in later-line NSCLC patients aligns with earlier ESMO data trends, and data from immuno-oncology pretreated cases suggest CS2009 may have the potential to reactivate immune responses. Additionally, CS2009 has shown early efficacy signals in several non-lung cancer indications, including a 40% ORR in non-clear cell renal cell carcinoma, 33.3% in soft tissue sarcoma, and encouraging trends in colorectal and ovarian cancers. Analysts believe this cross-indication performance enhances its platform development value. Regarding safety, Jefferies emphasized that CS2009 is well-tolerated overall, with no dose-limiting toxicities observed and no new safety signals identified. Goldman Sachs also indicated that the favorable safety profile should support subsequent Phase III clinical advancement and reduce uncertainties during the commercialization phase. Looking ahead, Jefferies pointed out that CS2009 is expected to see multiple key catalysts, including updated clinical data presentations at the 2026 ASCO and ESMO conferences, as well as the initiation of several global multicenter Phase III trials by the end of 2026, focusing on the core first-line NSCLC market. Goldman Sachs views future business development progress for CS2009 as a significant long-term value catalyst. Beyond CS2009, both institutions are also monitoring CStone’s ADC platform development. Jefferies mentioned that CS5001, a ROR1-ADC, has shown impressive results in a Phase I study, achieving 100% ORR and a 95.5% complete response rate in first-line combination therapy for diffuse large B-cell lymphoma. The company is also advancing next-generation ADC projects, including an ITGB4-ADC and a dual-target SSTR2/DLL3 ADC, with investigational new drug applications expected in the second half of 2026. Overall, both institutions generally agree that, supported by continued validation of CS2009’s clinical data and the gradual realization of its business development potential, CStone Pharmaceuticals is entering a phase of potential valuation reassessment.